Waters Podcast #1 :Current challenges in oligonucleotide analysis

August 19, 2009



Part of the podcast series: UPLC, QTof, HDMS, and more: A practical guide to the hottest techniques driving the future of biopharmaceutical science

As firms increasingly invest in biopharmaceutical development, there is a widespread need to educate scientists in new technologies and approaches in this rapidly evolving industry. For maximum effectiveness in drug development, the application of new techniques can save time and development costs. In this podcast series, we’ll provide you with a firm knowledge of the latest technological innovations in LC and LC/MS that have been designed to address and advance the very specific needs of the many applications areas in the biopharmaceutical laboratory.

Through a variety of topics highlighting our latest scientific work, this series will help you gain a better understanding of key bio-focused LC, MS, and software advancements. Learn how these solutions have been adopted by industry leaders around the world and how easy it is to implement the tools that deliver faster, better answers relating to the character and quality of your biopharmaceuticals.

In this episode, we discuss the many analytical challenges characterizing and quantitating therapeutic and diagnostic oligonucleotides. As the regulatory landscape becomes increasingly complex, manufacturers are faced with greater responsibility to meet requirements.

Presenter:
Sean McCarthy, PhD
Senior Research Chemist
Biopharmaceutical Business Operations
Waters Corporation
Milford, MA, USA